Ignite Creation Date:
2025-12-24 @ 2:04 PM
Ignite Modification Date:
2026-01-02 @ 10:41 PM
Study NCT ID:
NCT00461695
Status:
COMPLETED
Last Update Posted:
2013-08-27
First Post:
2007-04-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Influence of Persistent CMV-infection on Immune Senescence
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 183}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2007-05'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-08', 'completionDateStruct': {'date': '2010-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2013-08-26', 'studyFirstSubmitDate': '2007-04-17', 'studyFirstSubmitQcDate': '2007-04-17', 'lastUpdatePostDateStruct': {'date': '2013-08-27', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2007-04-18', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2008-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Geometric mean titer (GMT) of anti-TBEV-antibodies measured by TBEV-neutralisation assay and ELISA one month after each TBEV-vaccine administration in the group of CMV-seropositive versus CMV-seronegative individuals', 'timeFrame': 'One month after each TBEV-vaccine administration'}], 'secondaryOutcomes': [{'measure': 'Efficacy of TBEV-vaccination in healthy elderly individuals (Geometric mean antibody titer measured by TBEV-neutralisation test).', 'timeFrame': 'One month after 3rd TBEV-vaccine administration'}, {'measure': 'Safety of TBEV-vaccination in healthy elderly individuals.', 'timeFrame': 'One month after 3rd TBEV-vaccine administration.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Cytomegalovirus (CMV)', 'Tick-borne encephalitis virus (TBEV)', 'Ageing', 'Vaccine', 'Immunity'], 'conditions': ['Immune Senescence']}, 'descriptionModule': {'briefSummary': 'Recent studies indicate that persistent viral infections particularly with Cytomegalovirus (CMV) might have a negative impact on immune senescence (i.e. immunocompetence of elderly individuals). We will test this hypothesis by performing a vaccination trial in healthy elderly individuals subdivided in two groups of CMV-seropositive and CMV-seronegative individuals. All individuals will be vaccinated with the currently licensed vaccine for the prevention of TBE (FSME Immun CC) which is recommended for the general population in our area. Vaccination efficacy will be monitored longitudinally concerning the TBEV-specific antibody (TBEV-neutralization, TBEV-specific ELISA) and T cell response (ELISpot, cytokine production).\n\nVaccination efficacy will be compared between CMV+ and CMV- individuals and correlated with the CMV-specific immune response in CMV+ individuals.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['OLDER_ADULT'], 'minimumAge': '70 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion criteria:\n\n* Age \\> 70 years\n* Healthy according to a health questionnaire (completed before screening)\n* TBE-Vaccination indicated (exposure to TBEV-infested ticks possible)\n* Capable to make an informed decision and to understand the informed consent form\n* Informed consent signed by patient and study physician\n\nExclusion criteria:\n\n* Previous exposure to TBEV (natural or vaccination)\n* Immunodeficiency, history of autoimmune disease or current intake of immune-modulating drugs (corticosteroids a.s.o.)\n* Persistent (\\> 3 months) pharmacological treatment with more than one drug of relevance (exception: combination antihypertensives)\n* Contraindication for TBEV-vaccination\n* Condition that would drastically interfere with clinic attendance and/or adherence to the protocol\n* Past medical history or current treatment for one of the following conditions: Chronic cardiac disease (Coronary heart disease, heart failure), chronic pulmonary disease (COPD), chronic kidney disease, diabetes mellitus, previous stroke, epilepsy, Parkinsons disease, dementia\n* Hemoglobin \\<12 g/l\n* Random plasma glucose (RPG) \\> 11.1 mmol/l OR fasting plasma glucose (FPG) \\> 6.9 mmol/l (FPG required, if RPG is 7.0-11.0 mmol/l)\n* Calculated Creatinin-Clearance \\< 50 ml/min\n* TBEV-serology positive'}, 'identificationModule': {'nctId': 'NCT00461695', 'briefTitle': 'Influence of Persistent CMV-infection on Immune Senescence', 'organization': {'class': 'OTHER', 'fullName': 'University of Zurich'}, 'officialTitle': 'Influence of Persistent CMV-infection on Immune Senescence Evaluated With a Prospective Vaccination Trial Against Tick-borne Encephalitis Virus in Healthy Elderly Individuals (CYTEL-Study)', 'orgStudyIdInfo': {'id': 'CYTEL-Protocol V1.A1'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'OTHER', 'label': 'CMV-seropositive', 'description': 'Cytomegalovirus-seropositive individuals at screening (week 0). Intervention: Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.', 'interventionNames': ['Biological: Vaccination against TBEV (FSME Immun CC)']}, {'type': 'OTHER', 'label': 'CMV-seronegative', 'description': 'Cytomegalovirus-seronegative individuals at screening (week 0). Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.', 'interventionNames': ['Biological: Vaccination against TBEV (FSME Immun CC)']}], 'interventions': [{'name': 'Vaccination against TBEV (FSME Immun CC)', 'type': 'BIOLOGICAL', 'description': 'Intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.', 'armGroupLabels': ['CMV-seronegative', 'CMV-seropositive']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Zurich', 'country': 'Switzerland', 'facility': 'University Hospital Zurich, Department of Infectious Diseases and Hospital Epidemiology', 'geoPoint': {'lat': 47.36667, 'lon': 8.55}}], 'overallOfficials': [{'name': 'Urs Karrer, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University Hospital Zurich, Department of Infectious Diseases and Hospital Epidemiology'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Zurich', 'class': 'OTHER'}, 'collaborators': [{'name': 'Division of Infectious Diseases and Hospital Epidemiology', 'class': 'UNKNOWN'}], 'responsibleParty': {'type': 'SPONSOR'}}}}